Team McCallum

R&D for Lifetime of Life

Promising Alzheimer’s trial recruiting now.

Professor Norman Relkin is leading a phase III clinical trial of a promising Alzheimer’s treatment. The trial is currently looking for 360 patients from the US and Canada, diagnosed with mild to moderate Alzheimer’s, to take part.

Relkin reported yesterday, at a meeting of the American Academy of Neurology in Toronto, on the phase II trial results of IGIV (immune globulin intravenous), naturally occuring antibodies in human blood.

This treatment cut the brain shrinkage that occurs in Alzheimer’s significantly, with those responding best showing shrinkage at the same rate as controls without Alzheimer’s.

IGIV is already licensed for use in other medical conditions.

Click here for the Phase III trial enrollment site.


April 14, 2010 - Posted by | Alzheimer's, Health, IGIV, Norman Relkin, Success

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: